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ABSTRACT
Objective: The main objective of the present work was to prepare and evaluate creams of celecoxib inclusions which are nonsteroidal anti-
inflammatory drug to treat psoriatic arthritis.
Methods: Celecoxib inclusions were prepared using β-cyclodextrin to increase the solubility. These inclusions were incorporated in creams. Cocoa 
butter, triethanolamine, stearic acid, methylparaben, gum acacia, and coconut oil were used in cream preparation. Fourier transform infrared and 
differential scanning calorimetry studies were carried out for pure celecoxib and inclusions. Viscosity, pH, homogeneity, and type of emulsion under 
dye test were evaluation parameters done for creams.
Results: All the results obtained were within the limits and confirmed increased solubility of celecoxib inclusions.
Conclusion: From the results obtained, increase in solubility of celecoxib drug was confirmed by forming inclusions using β-CD as polymer.
Keywords: β-cyclodextrin, Psoriatic Arthritis, Creams, Celecoxib, Inclusions.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, systemic, and inflammatory 
disease that affects peripheral joints, connective tissues, and axial 
skeleton and is associated with psoriasis of skin and nails [1,2]. PsA 
is a seronegative inflammatory arthropathy that occurs in 5–7% of 
people with psoriasis [3,4]. It is thought that environmental triggers 
which are infectious in nature, triggers the disease in genetically 
susceptible individuals [5]. Currently available therapies for PsA are 
surgery, light therapy, narrowband ultraviolet (UV) B phototherapy, 
excimer laser, and psoralen and ultraviolet A (PUVA) [6]. Available 
drugs are corticosteroids, tacrolimus, tumor necrosis factor 
inhibitors, methotrexate, and sulfasalazine [7]. The disadvantages of 
these drugs are the radiation can dry out the skin and cause itching 
and redness, burning, blistering of the skin, etc. [8]. Celecoxib is a 
cyclooxygenase-2 (COX-2)-specific inhibiting agent that inhibits the 
conversion of arachidonic acid to the prostaglandins that mediate 
pain and inflammation [9]. In theory, a drug such as celecoxib that 
selectively inhibits COX-2 might block inflammation, pain, and fever 
[10]. Creams refer to disperse systems, in which one insoluble 
phase is dispersed as droplets in a second liquid phase. Creams are 
often preferred over other topical preparations because they are 
less irritating and easy to apply [11]. β-cyclodextrins are widely 
used in the pharmaceutical field for their ability of improving the 
solubility and the stability of drugs by complex formation at the 
solid state [12]. The use of cyclodextrins and their derivatives can 
encapsulate the bioactive compounds and protect the compounds 
from environmental conditions and improves the aqueous solubility 
and increases their capacity to function [13]. In the present study, 
an attempt has been made to develop inclusions (complexes) of 
celecoxib using β-CD. These inclusions are prepared to increase 
the solubility of the drug which is poorly water soluble. Prepared 
inclusions are incorporated into creams to obtain formulations for 
which further evaluation studies have been conducted.
METHODS
Celecoxib is a gift sample obtained from Wexford Laboratories Pvt., Ltd., 
Bengaluru. β-cyclodextrin was obtained from HiMedia, India. Cocoa 
butter was procured Rolex Chem Industries, India. Stearic acid and 
methylparaben were obtained from Qualikems Fine Chemicals Pvt. Ltd., 
Vadodara. Gum acacia was obtained from SD Fine-Chem Limited, Mumbai, 
triethanolamine from Pallav Chemicals and Solvents Pvt., Ltd., Boisar, 
India, and coconut oil from Herbs Nutri Products Pvt., Ltd., Mumbai.
Methodology
Solubility studies of celecoxib in water and in pH 7.4 buffer
Drug solubility was determined by adding excess amount of pure 
celecoxib in water and pH 7.4 phosphate buffer at 37±0.5°C in vials, 
respectively. These vials were kept in orbital shaker for 24 h at 
100 rpm. Final solution was filtered through membrane filter 0.45 µm. 
The concentration of the samples was measured using UV–visible 
spectrophotometer (UV 1800, Shimadzu, Japan). Each sample was 
analyzed in triplicate.
Analytical method for celecoxib
Calibration curve in pH 7.4 phosphate buffer
From the standard solution, a stock solution was prepared to give a 
concentration of 100 µg/ml in 7.4 buffer. Aliquots of 0.5, 1.0, 1.5, 2.0, and 
2.5 ml from the stock solution were pipetted out into 10 ml volumetric 
flasks. The volume was made up to the mark with 7.4 buffer. These 
dilutions gave 5, 10, 15, 20, and 25 µg/ml concentration of celecoxib, 
respectively. The absorbance of prepared solutions of celecoxib in 7.4 
buffer was measured at 252 nm spectrophotometrically against 7.4 buffer 
blank. Standard plot data of celecoxib in 7.4 pH buffer are reported in Fig. 1.
Fourier-transform infrared (FT-IR) spectroscopy analysis
FT-IR analysis was conducted to verify the interaction between drug 
and polymer. The sample powder was dispersed in KBr powder and 
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pellets were made by applying 4 kg/cm2 pressure. FT-IR spectra were 
obtained by powder diffuse reflectance on a FT-IR spectrophotometer 
type 8400S Shimadzu. It was performed for pure celecoxib drug and F2 
formulation.
Differential scanning calorimetry (DSC)
DSC was performed on pure drug and its formulations using DSC-60 
instrument. Calorimetric measurements were made with empty cell 
(high purity alpha alumina discs) as the reference. The dynamic scans 
were taken in nitrogen atmosphere at the heating rate of 10°C min−1. 
The energy was measured as J/Kcal. It was performed for pure celecoxib 
drug and F2 formulation.
Preparation of celecoxib cream
Oil-in-water (O/W) emulsion-based cream (semisolid formulation) 
was formulated. The emulsifier (stearic acid) and other oil-soluble 
components (cocoa butter, acetyl alcohol, and coconut oil) were 
dissolved in the oil phase (Part A) and heated to 75°C. The preservatives 
and other water-soluble components (methylparaben, triethanolamine, 
propylene glycol, and drug celecoxib inclusions) were dissolved in the 
aqueous phase (Part B) and heated to 75°C. After heating, the aqueous 
phase was added in portions to the oil phase with continuous stirring 
and perfume was added [14]. The formulations of different creams 
prepared are given in Table 1.
Evaluation of creams
Type of emulsion under dye test
The scarlet red dye is mixed with the cream. A drop of the cream was 
placed on a microscopic slide and then it was covered with a cover slip 
and examined under a microscope. If the disperse globules appear 
red and the ground is colorless, the cream is O/W type. The reverse 
condition occurs in W/O type cream, i.e., the disperse globules appear 
colorless in the red ground [15].
Appearance
The appearance of the cream was judged by its color, opalescence, and 
roughness and graded [15].
Homogeneity
The formulations were tested for the homogeneity by visual appearance 
and by touch [15].
pH
The pH meter was calibrated using standard buffer solution. About 
0.5 g of the cream was weighed and dissolved in 50.0 ml of distilled 
water and its pH was measured [15].
Viscosity
Viscosity of the formulation was determined by Brookfield Viscometer 
at 100 rpm, using spindle no. 7 [15].
In vitro drug diffusion studies
The F2 cream was permeated through a dialysis bag. A 0.5 g of cream 
was taken in the bag and is placed in a beaker containing phosphate 
buffer of pH 7.4 and constantly stirred with a small magnetic bead. 
During the experiment, temperature was maintained at 37±0.5°C to 
simulate the human skin condition. A 5 ml of samples were withdrawn 
at 0.5, 1, 2, 6, and 12 h and replaced with fresh receptor solution. The 
samples withdrawn were analyzed spectrophotometrically at 235 nm. 
The amount of drug released was calculated and the percentage drug 
released was plotted against time.
Similarly, it was done for pure drug.
Statistical analysis (Analysis of variance [ANOVA])
Both the study and control groups were compared. ANOVA is performed 
for cream F2 and pure drug to determine the differences among the 
products tested.
RESULTS AND DISCUSSION
Solubility studies of celecoxib in water and in pH 7.4 buffer
From the results obtained, it was confirmed that solubility of celecoxib 
is more in pH 7.4 buffer. Hence, further studies were carried out using 
pH 7.4 buffer. The results are given in Table 2.
Evaluation studies
Type of emulsion
Prepared cream was found to be O/W emulsion. It shows that the 
cream has good spreadability and penetration on applying on the skin. 
Furthermore, it can be washed of easily.
Appearance
Prepared creams were light cream in color, opaque.
Homogeneity
Prepared creams are homogenous. No aggregates are present in the 
formulation.
pH
pH of the prepared creams was in the range of 6–7. It shows that 
obtained pH is near to skin pH and it does not cause any skin irritation.
Table 2: Solubility studies for celecoxib
Concentration of celecoxib in 
water (µg/ml)




Table 1: Formulation chart of creams (F1-F3)
S. No. Ingredients F1 F2 F3
1. Celecoxib inclusions (mg) 50 50 50
2. Cocoa butter (g) 1 2 3
3. Stearic acid (g) 1 2 3
4. Gum Acacia (%) 0.5 1 1.5
5. Coconut oil (ml) 2 2 2
6. Methylparaben (%) 1 1 1
7. TEA (ml) 0.5 0.5 0.5
Fig. 1: Ultraviolet spectra of celecoxib in pH 7.4 phosphate buffer
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melting point of the drug was due to decrease in the crystallinity of the 
compound and also might be due displaced peak of drug.
In vitro drug release studies
In vitro drug release studies were carried out for both F2 formulation 
and pure drug. Pure drug has shown drug release for 8 h and after that 
no release was noticed, whereas F2 formulation has shown release till 
24 h (Max 91.78%). In case of F2 formulation, drug release occurred in 
prolonged manner. In the beginning, drug which is not encapsulated in 
the inclusions got released. This is the reason for increased % drug release 
during initial hours. Then, after attaining saturation state, drug release 
from inclusions occurred. This was seen till 24 h. However, in case of pure 
drug, no encapsulation of drug is seen hence release occurred till 8 h and 
also since celecoxib is poorly water soluble, drug release was also less. Drug 
release of both F2 formulation and pure drug is given in Table 4 and Fig. 7.
Statistical analysis (ANOVA)
ANOVA shows that in vitro results obtained by comparison between 
F5 and pure drug formulations have shown statistically significant 
differences (p < 0.05), as shown in Table 5.
Table 4: In vitro % drug release
S. No. Time F5 Pure drug
1. 0 0.00 0.00
2. 0.5 89.72 14.23
3. 1 76.98 28.45
4. 2 63.42 41.67
5. 4 59.43 54.82
6. 8 71.12 67.75
7. 12 82.43 -
8. 24 91.78 -
Table 3: Evaluation results of creams
S. No. Evaluation 
studies
F1 F2 F3
1. Appearance Light cream Light cream Light cream
2. Homogeneity No aggregates No aggregates No aggregates
3. Viscosity 2020 2040 2060
4. pH 6 7 7






F2 versus pure drug −20.16 37.42 Yes
Viscosity
It was carried out by Brookfield Viscometer. Obtained viscosity was in 
the range of 2020–2060. It shows that F3 has higher viscosity (2060) 
and F1 has lowest (2020).
All the obtained results are given in Table 3.
From the above results, it was found that F2 cream has high viscosity. 
Hence, it is considered for further studies such as FTIR and DSC. F2 
cream formulation is shown in Fig. 2.
FT-IR studies
The characteristic peaks of pure celecoxib and F2 formulation are shown 
in Fig. 3 and 4. From the data, it was observed that characteristic peaks 
of drug appeared almost similar in F2 spectrum with disappearance 
of some peaks. Hence, it can be inferred that there is no chemical 
interaction between drug and polymer and it can be concluded that the 
characteristic bands of pure drug were not affected by β-cyclodextrin 
and method used for preparation.
DSC
Thermogram of pure drug has shown a sharp endothermic peak at 
163.10°C, which corresponds to its melting point and is represented in 
Fig. 5. Formulation F2 has shown endothermic peak at 160.10°C which 
corresponds to the melting point of the drug and it is represented in Fig. 6. 
The DSC thermograms revealed that there was significant difference 
between the drug and the excipients. From the thermograms, it was evident 
that melting point of celecoxib was changed when it was formulated as 
complex. This was due to thermal transition behavior. Decrease in the 
Fig. 2: Prepared cream formulation (F2)
Fig. 3: Fourier transform infrared spectral data of pure celecoxib
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CONCLUSION
Solubility of celecoxib drug was increased by forming inclusions using 
β-CD as polymer. This further leads to increased bioavailability. From 
FT-IR and DSC studies, compatibility between drug and polymer was 
confirmed. All the results obtained from evaluation parameters found 
to be within the limits and state that prepared creams were having good 
spreadability and no skin irritation on topical use. Prolonged release of 
celecoxib drug from 8 h to 24 h was achieved. This helps in decreasing 
the dose frequency of drug thus increases patient compliance.
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